MBX Biosciences, Inc. Common Stock (MBX)
MBX Biosciences, Inc. (MBX) is a biotechnology company focused on developing treatments for metabolic and cardio-metabolic diseases. The company leverages its proprietary platforms to discover and develop novel therapeutics aimed at improving patient outcomes in conditions such as non-alcoholic steatohepatitis (NASH) and related metabolic disorders.
Company News
MBX Biosciences is conducting a public offering of 11,108,055 shares at $18.00 per share, expecting to raise approximately $199.9 million to support its precision peptide therapy development for endocrine and metabolic disorders.
MBX Biosciences has filed a registration statement for a proposed public offering of 10 million common stock shares, with an additional option for underwriters to purchase 1.5 million shares. The offering is subject to market conditions and has major investment banks as joint book-running managers.